9UK5 image
Deposition Date 2025-04-17
Release Date 2025-10-29
Last Version Date 2025-10-29
Entry Detail
PDB ID:
9UK5
Title:
crystal structure of the complex of interleukin-31 and its antibody
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.90 Å
R-Value Free:
0.23
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 21 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Interleukin 31
Gene (Uniprot):IL-31
Chain IDs:A
Chain Length:144
Number of Molecules:1
Biological Source:Canis lupus familiaris
Polymer Type:polypeptide(L)
Molecule:Antibody-H
Chain IDs:B (auth: H)
Chain Length:217
Number of Molecules:1
Biological Source:Canis lupus familiaris
Polymer Type:polypeptide(L)
Molecule:Antibody-L
Chain IDs:C (auth: L)
Chain Length:222
Number of Molecules:1
Biological Source:Canis lupus familiaris
Primary Citation
Structural insights into IL-31 signaling inhibition by a neutralizing antibody.
Structure ? ? ? (2025)
PMID: 41015037 DOI: 10.1016/j.str.2025.09.002

Abstact

Interleukin-31 (IL-31) signals through the IL-31 receptor alpha (IL-31RA) and oncostatin M receptor beta (OSMRβ) heterodimer, mediating pruritus, dermatitis, inflammatory responses, neuroimmune interactions, and certain cancers. Here, we present the crystal structure of canine IL-31 (cIL-31) in complex with a neutralizing caninized monoclonal antibody (2D10-2). This antibody competitively inhibited cIL-31 binding to canine OSMRβ (cOSMRβ) but not to canine IL-31RA (cIL-31RA). Moreover, it effectively blocked cIL-31-induced STAT5 phosphorylation in vitro and alleviated cIL-31-induced pruritus in beagle dogs. Structural analysis identified key antibody-binding residues in α-helical A, α-helical D, and the AB loop of cIL-31. Systematic mutagenesis based on the complex structure further defined the conformational epitopes of cIL-31 recognized by cOSMRβ. In summary, this study reports the IL-31 structure, revealing a four-α-helical bundle cytokine, and elucidates 2D10-2's neutralizing mechanism by targeting the cIL-31-cOSMRβ interaction. These findings advance our understanding of IL-31 and offer insights for developing IL-31-targeted therapeutics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures